Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Aβ oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.
The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Aβ oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.
Recent clinical advances using Aβ monoclonal antibodies that interact with both soluble Aβ oligomers and insoluble fibrillar Aβ, have demonstrated a reduction in Aβ burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Aβ approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.
PITTSBURGH, July 24 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the issuance by the Japan Patent Office and China’s National Intellectual Property
PITTSBURGH, July 09, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the receipt of a grant expected to total $3.3 million from the
PITTSBURGH, June 5, 2019 — Cognition Therapeutics, Inc., today announced that Anthony O. Caggiano, M.D., Ph.D. has joined the Company as chief medical officer (CMO). Cognition Therapeutics is a clinical stage neuroscience company focused on the protection and restoration of synaptic function in
Pittsburgh, April 05, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced that Mary Sano, Ph.D. of Mount Sinai School of
